Compare OWLT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | INKT |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.5M | 51.7M |
| IPO Year | N/A | 2021 |
| Metric | OWLT | INKT |
|---|---|---|
| Price | $15.27 | $11.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 352.0K | 20.6K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,640,000.00 | N/A |
| Revenue This Year | $36.68 | N/A |
| Revenue Next Year | $22.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.81 | N/A |
| 52 Week Low | $2.75 | $4.56 |
| 52 Week High | $16.82 | $76.00 |
| Indicator | OWLT | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 48.11 |
| Support Level | $11.92 | $11.33 |
| Resistance Level | $14.92 | $12.27 |
| Average True Range (ATR) | 1.24 | 0.77 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 68.37 | 38.72 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.